• Jeremy Y Ng and Kiran D Verma.
• Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, MDCL-2112, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada. Electronic address: ngjy2@mcmaster.ca.
• Diabetes Res. Clin. Pract. 2020 Oct 1; 168: 108365.

AimsType 2 diabetes (T2D) is a condition where the body becomes insulin resistant and cannot use insulin made by the pancreas or is relatively insulin deficient causing high blood glucose levels. Assessing the quality of clinical practice guidelines (CPGs) for T2D is important to identify knowledge gaps and where improvements can be made. The purpose of this review was to identify the quantity and assess the quality of CPGs for the treatment and/or management of T2D.MethodsA systematic review was conducted to identify T2D CPGs. MEDLINE, EMBASE, CINAHL and GIN were searched from 2008 to 2018. Eligible guidelines published on the treatment and/or management of T2D were assessed with the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument.ResultsSeventeen CPGs were found to be eligible. Scaled domain percentages (highest to lowest) were: clarity of presentation (81.2%), scope and purpose (77.1%), stakeholder involvement (52.8%), applicability (42.9%), rigour of development (41.5%), and editorial independence (35.1%).ConclusionsCPGs that achieved higher AGREE II scores and favourable overall recommendations could be used by healthcare providers to facilitate informed discussions surrounding T2D therapies. CPGs that received lower scaled domain percentages or overall recommendations could be improved by using the AGREE II instrument.Copyright © 2020 Elsevier B.V. All rights reserved.

10 keywords...

hide…